The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.
Adult patients over 18 years of age
Lung transplant candidates with positive CMV IgG
Anticipated to receive a lung transplant (both double lung and single lung)
Negative CMV IgG prior transplant
Pregnant or breastfeeding women
HIV infected patients
Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
Participants attending the Miami Transplant Institute.
Cohort
Prospective
Not listed
Positive CMV Immunoglobulin (IgG) positive lung transplant
Positive CMV Immunoglobulin (IgG) measured by IU/ml
Graft Outcome status
Graft Outcome status measured by number of rejection based on forced expiratory volume in 1 second( FEV1) /Forced vital capacity (FVC) ratio. A calculated ratio that helps diagnose obstructive and restrictive lung diseases
Number of dead participants
Number of dead participants measured by numbers of death
Duration of CMV medication
Duration of CMV medication measured by treatment days
Number of patients with CMV-positive results
CMV disease measured by the number of patients with CMV-positive results
Click on the lead sponsor to view all of their trials.
University of Miami
Lead sponsor
Eurofins Viracor
Collaborator
